Path to market: PRR has a path to market – it can follow Dendreon (DNDN US, not rated) which is in the US market with Provenge, an immunotherapy prostate cancer
recurrence vaccine. As a fast follower, we believe PRR’s manufacturing technology has the potential to BETTER THAN DNDN’s."
From the Nomura Report.
Path to market: PRR has a path to market – it can follow...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $670.1K | 1.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 44785 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 22453 | 2 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |